×
About 88 results

ALLMedicine™ Cholangiocarcinoma Center - News

Pemazyre™ (pemigatinib) - Official Pemazyre HCP Website‎
https://hcp.pemazyre.com

Visit A Site For Healthcare Professionals To Learn Important Information On Pemazyre. Discover A Treatment Option For Your Patient And Read About The Usage And Indications. Recommended Dosing. Safety Profile. Clinical Response Rates. Prescribing Information.

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
http://ascopubs.org/doi/full/10.1200/JCO.18.02178

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS Three phase III randomized c...

FGFR Inhibitor Tested in Hard-to-Treat GI Cancer
https://www.onclive.com/publications/oncology-live/2018/vol-19-no-1/fgfr-inhibitor-tested-in-hardtotreat-gi-cancer

Jan 11th, 2018 - Milind Javle, MD Given that few options are available for intrahepatic cholangiocarcinoma (ICC), investigators are excited about a phase III trial of the multikinase inhibitor derazantinib (ARQ 087) as a second-line treatment for patients with inoperable or advanced disease. Current options are particularly limited for patients who experience disease progression after standard-of-care first-lin...

Liver Cancer Linked to Metabolic Syndrome
https://www.medpagetoday.com/cardiology/metabolicsyndrome/27758

Jul 27th, 2011 - Action Points Explain that an analysis of data from the SEER database showed that both hepatocellular carcinoma and intrahepatic cholangiocarcinoma were significantly associated with the metabolic syndrome. Note that the incidence of both types of liver cancer and metabolic syndrome are increasing in the U.S. Patients with metabolic syndrome had as much as a twofold increased risk of liver canc...

Radiotherapy Effective in Common Liver Tumor
https://www.medpagetoday.com/hematologyoncology/othercancers/54387

Oct 29th, 2015 - Action Points Note that this observational study found that higher doses of radiation were associated with better survival among patients with inoperable intrahepatic cholangiocarcinoma. Be aware that, as this was not a randomized trial, the effects of patient selection may drive a component of these results. Delivery of higher doses of radiotherapy (RT) improves local control (LC) and overall ...

Adjuvant Therapy for Biliary Tract Cancers Advance
https://www.onclive.com/publications/oncology-live/2017/vol-18-no-23/adjuvant-therapy-for-biliary-tract-cancers-advance

Dec 27th, 2017 - Laura W. Goff, MD   Associate Professor, Medicine Associate Director, Hematology/ Oncology Fellowship Program Marc Roth, MD   Resident Department of Internal Medicine Vanderbilt-Ingram Cancer Center Nashville, Tennessee Biliary tract cancers (BTCs) are rare but deadly diseases, subdivided into intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcin...

Adding Surgery or RT to Chemo May Up Survival in Advanced ICC
https://www.medpagetoday.com/hematologyoncology/othercancers/82197

Sep 17th, 2019 - Adding hepatic surgery or irradiation to chemotherapy improved overall survival versus chemotherapy alone in patients with metastatic intrahepatic cholangiocarcinoma (ICC), a large cohort study found. Although the number of patients given added liver-directed local therapy (LDLT) was small, median overall survival was 16.7 months (95% CI 13.4-19.6) for those receiving hepatic resection or defin...

Surveillance for hepatobiliary cancers in primary sclerosing cholangitis
https://www.mdedge.com/internalmedicine/article/209796/hepatology/surveillance-hepatobiliary-cancers-primary-sclerosing?channel=75
Bianca Nogrady

Oct 9th, 2019 - All adult patients with primary sclerosing cholangitis should be screened at least annually for cholangiocarcinoma and gallbladder cancer, particularly in the first year after their diagnosis, according to a clinical update published in Clinical Gastroenterology and Hepatology. Individuals with primary sclerosing cholangitis have a 400-fold higher risk of cholangiocarcinoma, compared with the g.

Combo Tx Helpful for Selected Unresectable ICC Patients
https://www.medpagetoday.com/hematologyoncology/othercancers/83093

Nov 1st, 2019 - The combination of locoregional treatment approaches with systemic chemotherapy may offer improved outcomes for some patients with unresectable intrahepatic cholangiocarcinoma (ICC), according to the results of two single-arm, phase II studies. The first trial, by Julien Edeline, MD, of Centre Eugene Marquis in France, and colleagues, tested first-line radioembolization plus chemotherapy. Among...

AGA CPU: Surveillance for hepatobiliary cancers in primary sclerosing cholangitis
https://www.mdedge.com/gihepnews/article/209796/hepatology/aga-cpu-surveillance-hepatobiliary-cancers-primary-sclerosing?channel=346
Bianca Nogrady, MDedge News

Oct 9th, 2019 - All adult patients with primary sclerosing cholangitis should be screened at least annually for cholangiocarcinoma and gallbladder cancer, particularly in the first year after their diagnosis, according to a clinical update published in Clinical Gastroenterology and Hepatology. Individuals with primary sclerosing cholangitis have a 400-fold higher risk of cholangiocarcinoma, compared with the g.

mIDH1 inhibitor ivosidenib improves progression-free survival in advanced cholangiocarcinoma
https://www.mdedge.com/fedprac/article/209208/gastroenterology/midh1-inhibitor-ivosidenib-improves-progression-free?channel=53
Sharon Worcester

Oct 1st, 2019 - BARCELONA – Ivosidenib, a first-in-class, oral, small-molecule inhibitor of the mutant isocitrate dehydrogenase 1 (mIDH1) protein, significantly improved progression-free survival, compared with placebo, for the treatment of advanced cholangiocarcinoma in the global, randomized, phase 3 ClarIDHy trial. A trend toward favorable overall survival was also seen in the pivotal double-blind trial, Gh.

AGA Clinical Practice Update: Surveillance for hepatobiliary cancers in primary sclerosing cholangitis
https://www.mdedge.com/gihepnews/article/209796/hepatology/aga-clinical-practice-update-surveillance-hepatobiliary-cancers?channel=346
Bianca Nogrady, MDedge News

Oct 9th, 2019 - All adult patients with primary sclerosing cholangitis should be screened at least annually for cholangiocarcinoma and gallbladder cancer, particularly in the first year after their diagnosis, according to a clinical practice update published in Clinical Gastroenterology and Hepatology. Individuals with primary sclerosing cholangitis have a 400-fold higher risk of cholangiocarcinoma, compared w.

November 2019
https://www.mdedge.com/gihepnews/article/211213/november-2019?channel=29259

Oct 30th, 2019 - Q1. Correct answer: F Rationale There are a number of known risk factors for cholangiocarcinoma including PSC, choledochal cysts, obesity, chronic liver disease, toxins such as Thorotrast as well as liver flukes including those in the Opisthorchis and Clonorchis genus.

Asymptomatic primary squamous cell carcinoma of the liver
https://www.mdedge.com/hematology-oncology/article/80540/gastroenterology/asymptomatic-primary-squamous-cell-carcinoma
Azriel Avezbadalov et al

Feb 20th, 2014 - An elderly woman with a family history of cholangiocarcinoma is diagnosed with primary squamous cell carcinoma of the liver after clinical evaluation, imaging, and tumor markers suggest that metastatic SCC to the liver was not likely. Click on the PDF icon at the top of this introduction to read the full article.

Hints of nivolumab efficacy seen in biliary tract cancers
https://www.mdedge.com/hematology-oncology/article/168769/gastroenterology/hints-nivolumab-efficacy-seen-biliary-tract
Neil Osterweil

Jun 25th, 2018 - BARCELONA – The immune checkpoint inhibitor nivolumab (Opdivo) shows activity against biliary tract cancers (BTC) that have progressed on prior systemic therapies, investigators report. Among 27 patients with intra- and extrahepatic cholangiocarcinoma and cancers of the gallbladder for whom at least one prior line of therapy had failed, the overall response rate with nivolumab monotherapy was 1.

Severe eosinophilia associated with cholangiocarcinoma
https://www.mdedge.com/hematology-oncology/article/108410/gastroenterology/severe-eosinophilia-associated
Daniela Tirotta et al

Apr 27th, 2016 - It is widely recognized that eosinophils are found in tumor infiltrates and that their mechanism of action is associated with particular symptoms and prognosis. However, the causes of and reasons for this process remain unclear, as does the exact mechanism by which it occurs.

Refractory FGFR-altered cholangiocarcinoma responds to FGFR kinase inhibitor
https://www.mdedge.com/gihepnews/article/153303/gastroenterology/refractory-fgfr-altered-cholangiocarcinoma-responds-fgfr
Chhavi Jain, MDedge News

Dec 2nd, 2017 - BGJ398, a first-in class pan–fibroblast growth factor receptor (pan-FGFR) kinase inhibitor, had modest clinical activity and a manageable toxicity profile, according to results of a phase 2 study of 61 patients with chemotherapy-refractory, advanced or metastatic cholangiocarcinoma with alterations in genes encoding FGFR. FGFR-2 fusion mutations are found in 13% to 17% of patients with intrahep.

Surgical infections, early discharge hike readmissions in extrahepatic cholangiocarcinoma
https://www.mdedge.com/hematology-oncology/article/116402/surgical-oncology/surgical-infections-early-discharge-hike
Michele G. Sullivan

Oct 26th, 2016 - WASHINGTON – Hospital readmissions are common after resection of extrahepatic cholangiocarcinoma, with about 20% of patients returning in the first 90 days after surgery. Two factors – surgical site infections and an abbreviated length of stay – both quadrupled the risk of readmission, Michail Mavros, MD, said at the American College of Surgeons Clinical Congress.

Neoadjuvant chemoradiation may give transplant the edge over resection in biliary cancer
https://www.mdedge.com/hematology-oncology/article/135349/general-surgery/neoadjuvant-chemoradiation-may-give-transplant
Damian McNamara

Apr 7th, 2017 - MIAMI BEACH – Survival for patients with hilar cholangiocarcinoma was similar between those who underwent transplantation and those who underwent resection, but neoadjuvant therapy may give transplant strategy the edge, findings of a study and meta-analysis suggest. “Neoadjuvant chemoradiation therapy is clearly a factor that affects patient survival, and may be the only reason the patients who.